Shares of Hims & Hers (HIMS) are down $3.47, or 8%, to $37.50 in pre-market trading after a court denied a motion for a preliminary injunction that two compounding groups – the Outsourcing Facilities Association and North American Custom Laboratories – filed in a bid to stop the FDA from removing Eli Lilly’s (LLY) tirzepatide from the shortage list. Hims & Hers is a compounder of the weight loss drug whose shares are often volatile around news regarding shortages of Novo Nordisk’s (NVO) Ozempic and Wegovy injections Eli Lilly’s (LLY) own injectable weight-loss drug, marketed as Zepbound.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Novo takes ‘direct shot’ at Hims & Hers with NovoCare , says Citi
- Hims & Hers Health Faces Increased Competition and Regulatory Challenges Amid Uncertain Revenue Projections
- Analysts Have Mixed Reviews on Hims & Hers Stock Amid Uncertainty Around Weight Loss Business
- Wegovy Gets Cheaper! Novo Nordisk Takes on Eli Lilly as Obesity Drug Battle Heats Up
- Hims & Hers’ weight loss strategy validated by Novo DTC offering, says BofA